IMPACT BIOMEDICAL INC. amended Amendment No. 1 to the Merger and Share Exchange Agreement with Dr Ashleys Limited, Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited, Kanans Visvanats (effective 2026-02-27).
“On February 27, 2026, the parties entered into Amendment No. 1 to the Merger and Share Exchange Agreement (the “Amendment to the Original Merger and Share Exchange Agreement” and, together with the Original Merger and Share Exchange Agreement, the “Merger and Share Exchange Agreement”).”
Chan Heng Fai Ambrose was appointed as Director at IMPACT BIOMEDICAL INC..
“On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date.”
Jason T. Grady was appointed as Director at IMPACT BIOMEDICAL INC..
“Additionally on June 6, 2024, the Board of Directors of the Company appointed Jason T. Grady to serve as a Director of the Company, effective as of the same date.”
Heng Fai Ambrose Chan resigned as Director at IMPACT BIOMEDICAL INC..
“On June 6, 2024, Heng Fai Ambrose Chan notified Impact Biomedical, Inc. (the “Company”) that he is resigning as a member of the Board of Directors of the Company, effective immediately.”
Material Agreements
IMPACT BIOMEDICAL INC. amended Amended Revolving Promissory Note dated March 1, 2023 with DSS, Inc. valued at Principal balance of $12,859,328.60; maturity extended to September 30, 2030; WSJ Prime + 0.50% floa (effective 2024-01-18).
“Effective January 18, 2024, DSS, Inc., a New York corporation ("DSS") and Impact BioMedical, Inc., a Nevada corporation ("Impact") entered into an amendment to the revolving promissory note dated March 1, 2023 (the "Original Note"), whereby DSS loaned Impact an original amount of up to $12,000,000 (the "Loan").”
Material Agreements
IMPACT BIOMEDICAL INC. entered into Share Exchange Agreement with DSS BioHealth Security, Inc. (effective 2023-10-31).
“Impact BioMedical, Inc. (the “Company”), entered into a Share Exchange Agreement (the “Exchange Agreement”) with DSS BioHealth Security, Inc. (“DBH”), pursuant to which, DBH agreed to exchange 60,496,091 shares of the Company’s common stock for 60,496,091 shares of Series A Convertible Preferred Stock”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.